Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
March 16, 2023 16:24 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic...
22157.jpg
Acute Lung Injury Treatment Global Market Report 2023: R&D of Novel Therapies Enhancing Acute Lung Injury Treatment Growth
March 16, 2023 08:18 ET | Research and Markets
Dublin, March 16, 2023 (GLOBE NEWSWIRE) -- The "Global Acute Lung Injury Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
March 14, 2023 16:01 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
22157.jpg
Global Acute Respiratory Distress Syndrome Devices Market Report 2023: North America Remains the Global Leader - Growth Trends, Key Players, Competitive Strategies and Forecasts to 2031
March 02, 2023 07:08 ET | Research and Markets
Dublin, March 02, 2023 (GLOBE NEWSWIRE) -- The "Global Acute Respiratory Distress Syndrome Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players,...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger
February 27, 2023 16:05 ET | Adamis Pharmaceuticals Corporation
Combined company will have commercial products and a library of development candidates, two of which are clinical stageWill be under the leadership of DMK CEO, Dr. Ebrahim (Eboo) Versi MD, PhDLead...
Adamis Pharmaceuticals logo
Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements
February 22, 2023 16:01 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update
November 07, 2022 16:05 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
FINAL_VeruIncLogo_RGB_300dpi.jpg
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
October 24, 2022 08:30 ET | Veru Inc.
MIAMI, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
Adamis Pharmaceuticals logo
Adamis Announces Review of Strategic Alternatives
October 03, 2022 16:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
August 12, 2022 17:00 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as...